Huntington’s community grieves not just one therapeutic setback, but two
For the community of people affected by Huntington’s disease — a group that is no stranger to disappointment — the back-to-back announcements last month still hit like a double whammy.
First, Roche announced it was cutting off the dosing of its experimental therapy tominersen, in a closely watched, much-hyped Phase 3 clinical trial. Then, a week later, Wave Life Sciences said it was abandoning two Huntington’s therapies in earlier stage trials.
Read Original Article: Huntington’s community grieves not just one therapeutic setback, but two »
